Bettina Hamelin
Bettina Hamelin is the Chief Executive Officer of Innovative Medicines Canada, the leading lobby group representing patented drug manufacturers in Canada. With a strong background in health policy and advocacy, she has been a prominent voice in the pharmaceutical industry, advocating for structural reforms, investment in innovative medicines, and ensuring patient access to essential medications. Recently, she has been in the news for emphasizing the need for the Canadian government to act on the recommendations of a pharmaceutical task force aimed at navigating geopolitical challenges and enhancing the regulatory landscape for drug approvals.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Canada | 1 | 6.00 | 0.08% | +0% | 38,005,238 | 31,254 | $1,700,000 | 1,398$ |
| Totals | 1 | 38,005,238 | 31,254 | $1,700,000 | 1,398$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Bettina Hamelin, IMC’s chief executive officer, said the report must translate into urgent action.
6